Biocon · NSE: BIOCON · BSE: 532523
Q2 FY26 results · Jul–Sep 2025
Biocon reported revenue from operations of ₹4,295.50 crore (up 19.6% from Q2 FY25) and net profit of ₹132.80 crore (up 390.0% from Q2 FY25) for Q2 FY26 (Jul–Sep 2025), on a consolidated basis.
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 4,295.50 | 3,590.40 | +19.6% | 3,941.90 | +9.0% |
| Other income | 93.00 | 32.50 | +186.2% | 79.70 | +16.7% |
| Total income | 4,388.50 | 3,622.90 | +21.1% | 4,021.60 | +9.1% |
| Profit before tax | 171.30 | 98.40 | +74.1% | 96.90 | +76.8% |
| Net profit for the period | 132.80 | 27.10 | +390.0% | 89.20 | +48.9% |
| Attributable to shareholders of the company | 84.50 | (16.00) | Turned profit | 31.40 | +169.1% |
| EPS, basic (₹) | 0.66 | (0.13) | not comparable | 0.26 | +153.8% |
| Net margin (%) | 3.1 | 0.8 | 2.3 |
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 583.30 | 525.40 | +11.0% | 537.10 | +8.6% |
| Other income | 133.80 | 73.50 | +82.0% | 61.30 | +118.3% |
| Total income | 717.10 | 598.90 | +19.7% | 598.40 | +19.8% |
| Profit before tax | 85.70 | 20.90 | +310.0% | (7.60) | Turned profit |
| Net profit for the period | 70.90 | 3.20 | 22x | (8.30) | Turned profit |
| EPS, basic (₹) | 0.55 | 0.03 | 18x | (0.07) | Turned profit |
| Net margin (%) | 12.2 | 0.6 | -1.5 |
Consolidated
- Filed with BSE
- 11 Nov 2025, 21:16 IST
- Board meeting
- 11 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 11 Nov 2025, 21:16 IST
- Board meeting
- 11 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE